Skip to main content

Table 1 Frequencies of amino acid substitutions detected in HCV NS5A protein from mono-infected and HIV/HCV co-infected patients

From: Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil

Amino acid residues HCV (n = 156) HIV/HCV (n = 101)
1a (n = 41) 1b (n = 84) 3a (n = 31) 1a (n = 77) 1b (n = 9) 3a (n = 15)
M/L28a V (1; 2.4%) V (1; 1.2%)  
  I (1; 2.4%) I (3; 3.9%)  
  L (1; 2.4%)  
  P (1; 1.2%)  
  T (1; 1.3%)  
Q/R/A30a H (4; 9.8%) H (1; 1.3%)  
  R (1; 2.4%) R (1; 1.3%)  
  K (1; 1.2%) K (5; 16.1%)  
  Q (3; 3.6%) Q (1; 11.1%)  
  S (1; 3.2%) S (1; 6.7%)
  L (1; 1.3%)  
L31 F (1; 1.2%)  
  V (2; 2.4%)  
Y93 H (2; 2.4%) H (2; 6.5%) H (1; 11.1%)  
Total (RAS) 14.6% (6/41) 6.0% (5/84) 22.6% (7/31) 3.9% (3/77) 11.1% (1/9) 0% (0/15)
  1. HCV hepatitis C virus and HIV human immunodeficiency virus
  2. aNS5A: M28 and Q30 are the dominant amino acids in GT-1a; L28 and R30 are the dominant amino acids in GT-1b; M28 and A30 are the dominant amino acids in GT-3a
  3. Bold type represents the clinically relevant resistance-associated substitution (RAS). Data interpreted according to cited references [5, 23, 27, 33, 39,40,41,42]